RCL vs STRO · P/E 26, rev $16.48B vs rev $62.0M
Royal Caribbean Cruises Ltd (RCL) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported RCL revenue for 2024-12-31 was $16.48B. Net income was $2.90B. Revenue was up 18.6% from 2023-12-31 to 2024-12-31. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
RCL currently screens at market cap $85.57B and trailing P/E 25.7. STRO currently screens at market cap $470.8M.
Not investment advice. Open the RCL and STRO stock pages for the full models.
Not investment advice.